Choice Institutional Equities Maintains Buy on Zydus Lifesciences
The brokerage maintains its positive view, citing a specialty and complex-products pipeline, and projects 17.2% revenue CAGR in FY26–29E.
The brokerage maintains its positive view, citing a specialty and complex-products pipeline, and projects 17.2% revenue CAGR in FY26–29E.